Compare CMC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMC | CRSP |
|---|---|---|
| Founded | 1915 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.1B |
| IPO Year | 1987 | 2016 |
| Metric | CMC | CRSP |
|---|---|---|
| Price | $80.33 | $45.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 20 |
| Target Price | $71.10 | ★ $71.95 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 03-19-2026 | 02-11-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ 235.90 | N/A |
| EPS | ★ 3.85 | N/A |
| Revenue | ★ $8,009,185,000.00 | $38,337,000.00 |
| Revenue This Year | $17.16 | N/A |
| Revenue Next Year | $6.68 | $1,376.73 |
| P/E Ratio | $21.48 | ★ N/A |
| Revenue Growth | ★ 2.25 | N/A |
| 52 Week Low | $37.92 | $30.04 |
| 52 Week High | $84.12 | $78.48 |
| Indicator | CMC | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 33.36 |
| Support Level | $74.66 | $49.10 |
| Resistance Level | $84.12 | $53.00 |
| Average True Range (ATR) | 2.55 | 3.16 |
| MACD | 0.28 | -0.78 |
| Stochastic Oscillator | 65.92 | 0.14 |
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.